Ipsen : CA T1 2024 : plutôt supérieur aux attentes du consensus
>CA T1 2024 : +13,3% : bon niveau d’organique - Le CA T1 2024 atteint 822,4 M€, +10,9% (+13,3% à tcc.) avec un CA Oncologie, à +7,5% à tcc., Maladies Rares à +69% à tcc. (avec toutefois l’entrée dans le périmètre de Sohonos) et Neurosciences à 19,6% à tcc..Les effets devises ont un impact de près de -2,5% sur ce T1.Le groupe réaffirme ses guidances (croissance de 6% à tcc. et MOP. d’environ 30%).Les grandes franchises sont solides – Les nouveaux...Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.